Most uterine polyps are benign, but a small percentage harbor cancer. Across a large meta-analysis of more than 35,000 women, roughly 3 in every 100 uterine polyps turned out to be malignant. That number shifts considerably depending on age, symptoms, and other individual risk factors, which makes understanding who is at higher risk and how these polyps are evaluated critically important. The biology behind cancerous polyps, the warning signs they produce, and the way they are treated all differ in meaningful ways from ordinary benign polyps.
How Often Uterine Polyps Turn Out to Be Cancerous
A systematic review and meta-analysis pooling data from 51 studies and over 35,000 women found that the overall rate of cancer within uterine polyps was about 2.7%. That is a useful average, but the spread was wide depending on the population studied. Among premenopausal women the rate dropped to around 1%, while among postmenopausal women it climbed to nearly 5%.1PubMed. The risk of malignancy in uterine polyps: A systematic review and meta-analysis In one histopathologic study of roughly 500 polyps, about 70% were entirely benign, a quarter showed some degree of hyperplasia (overgrowth of the lining cells), and under 1% were frankly cancerous, with another 3% showing the kind of atypical hyperplasia that is considered a precursor to cancer.2PubMed. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps
These numbers explain why clinicians do not rush every woman with a polyp into surgery, but they also explain why polyps are never dismissed outright. A 3% average risk means the vast majority of polyps are harmless, yet in specific subgroups the odds are high enough to warrant removal and examination under a microscope.
Symptoms That Raise Concern
The single most common symptom associated with cancerous uterine polyps is abnormal uterine bleeding. For postmenopausal women, any vaginal bleeding is considered abnormal and warrants investigation. One study found that endometrial tumors within polyps were seen exclusively in postmenopausal women who had bleeding, and were absent in those without it.3PubMed. Endometrial polyps in postmenopausal women Across the broader literature, women with symptoms had a malignancy rate of about 5%, compared to roughly 2% in women whose polyps were discovered incidentally on imaging.1PubMed. The risk of malignancy in uterine polyps: A systematic review and meta-analysis
For premenopausal women, the picture is murkier. Abnormal bleeding in this group is extremely common for non-cancerous reasons, and at least one study found that bleeding alone was not a reliable predictor of malignancy in premenopausal polyps. Instead, polyp size and the presence of multiple polyps were more telling.4PubMed Central. Risk Factors Associated with the Malignant Changes of Symptomatic and Asymptomatic Endometrial Polyps in Premenopausal Women So while bleeding is the classic red flag, especially after menopause, absence of bleeding does not guarantee a polyp is safe, and bleeding in younger women does not necessarily point to cancer.
Other symptoms are less specific. Some women report pelvic pain, unusually heavy periods, or spotting between cycles. These overlap almost completely with the symptoms of benign polyps, fibroids, and a dozen other gynecologic conditions, which is why the symptom alone rarely clinches a diagnosis.
Who Is at Higher Risk
Several factors consistently push the risk of a cancerous polyp higher. A meta-analysis of studies on hysteroscopically resected polyps identified three major ones: abnormal uterine bleeding, being postmenopausal, and age over 60. Women over 60 had roughly two and a half times the risk compared to younger women.5PubMed. Factors Associated with Malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and Meta-Analysis
Obesity and high blood pressure also appear in multiple studies as independent risk factors. One study found that the majority of its patients with malignant polyps had one or more of these metabolic conditions, often alongside a history of unopposed estrogen exposure.6PubMed. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps Elevated fasting blood glucose and markers of chronic inflammation have also been linked to higher odds of malignancy within polyps.7PubMed Central. Malignancy risk factors based on endometrial polyp
Polyp size matters, too. In one decision-tree analysis of postmenopausal women, a polyp diameter greater than 13 mm on ultrasound was the strongest predictor of precancerous or cancerous change. Body mass index and whether the polyp looked cystic or solid on ultrasound further stratified women into low, intermediate, and high-risk categories.8PubMed Central. Risk of Pre-Malignancy or Malignancy in Postmenopausal Endometrial Polyps: A CHAID Decision Tree Analysis Among premenopausal women, polyp volume greater than 10 mL carried nearly six times the odds of a precancerous or malignant finding.4PubMed Central. Risk Factors Associated with the Malignant Changes of Symptomatic and Asymptomatic Endometrial Polyps in Premenopausal Women
The Tamoxifen Connection
Tamoxifen, a medication widely used in the treatment and prevention of breast cancer, deserves its own mention because of how strongly it is tied to uterine polyps and their potential for malignancy. Tamoxifen acts as an estrogen blocker in breast tissue but has estrogen-like effects on the uterine lining, which can stimulate polyp growth. A large cohort study found that tamoxifen use was associated with nearly four times the risk of developing endometrial polyps and a similarly elevated risk of endometrial cancer.9JAMA Network Open. Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
Polyps that form under tamoxifen’s influence tend to have a higher rate of malignant change than polyps in the general population. Reported rates of cancer within tamoxifen-related polyps range from about 3% to over 10%, compared to under 1% in the general population in the same studies.10PubMed Central. The effect of tamoxifen on the genital tract One study specifically comparing tamoxifen-treated breast cancer patients to controls found that 3% of polyps in the tamoxifen group were malignant versus 0.5% in the control group.11PubMed. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients Because of this, women on tamoxifen are typically monitored more closely and any uterine polyps found are treated with a lower threshold for removal.
How Cancerous Polyps Are Diagnosed
A uterine polyp is usually first spotted on a transvaginal ultrasound. On imaging, benign polyps tend to look round with clear borders and uniform echoes. Malignant polyps are more likely to show irregular borders, mixed echogenicity, and increased blood flow.12PubMed Central. Analysis of ultrasonic imaging changes and factors related to malignant transformation in postmenopausal patients with endometrial polyps Advanced Doppler ultrasound can add more information by measuring blood flow resistance within the polyp. Malignant polyps tend to show lower resistance to blood flow, reflecting the new, leaky blood vessels that tumors recruit. One study found that contrast-enhanced Doppler could help distinguish cancerous lesions from benign polyps based on these flow differences.13Ultrasound in Obstetrics & Gynecology. Flow differences between endometrial polyps and cancer: a prospective study using intravenous contrast‐enhanced transvaginal color flow Doppler and three‐dimensional power Doppler ultrasound
Ultrasound alone, however, cannot confirm cancer. The gold standard is to obtain tissue for examination under a microscope. Hysteroscopy, where a thin camera is passed through the cervix to directly visualize and sample the uterine lining, is far more reliable than blind curettage. In one head-to-head comparison, curettage correctly diagnosed only about 8% of endometrial polyps, while hysteroscopy caught the vast majority of lesions that curettage missed.14Journal of Obstetrics and Gynaecology Research. Prospective comparison of biopsy results from curettage and hysteroscopy in postmenopausal uterine bleeding Another study found that hysteroscopy left only 4 cases of endometrial pathology undiagnosed compared to 21 missed by curettage.15PubMed. Hysteroscopy with directed biopsy versus dilatation and curettage for the diagnosis of endometrial hyperplasia and cancer in perimenopausal women Clinical guidelines now recommend that postmenopausal women with bleeding and a suspected polyp be offered hysteroscopy with removal if a polyp is found, rather than a wait-and-see approach.16PubMed. Endometrial polyps. An evidence-based diagnosis and management guide.
Treatment When Cancer Is Found
If a polyp turns out to contain cancer, the treatment path depends on the type and extent of the disease. The standard treatment for endometrial cancer is a hysterectomy, typically with removal of the ovaries and fallopian tubes, along with surgical staging to check whether the cancer has spread to lymph nodes or other structures. For high-grade cancers such as serous or clear cell types, even when apparently confined to a polyp, staging surgery that includes lymph node sampling and peritoneal washings is usually performed.17International Journal of Gynecological Cancer. An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma
An important clinical question is whether simply removing the polyp by hysteroscopy is enough. The research says, in most cases, no. One study directly evaluating hysteroscopic polypectomy for premalignant and malignant polyps concluded that polypectomy alone was insufficient to reliably eradicate the disease. The surrounding endometrium can harbor residual cancer that the hysteroscope does not detect.18PubMed. Hysterscopic Resection of Premalignant and Malignant Endometrial Polyps: Is it a Safe Alternative to Hysterectomy? The exception is women who strongly wish to preserve fertility. In carefully selected younger patients with early-stage disease, hysteroscopic removal followed by progestin therapy can be considered, though this carries a higher risk of recurrence and requires intensive follow-up.19European Journal of Surgical Oncology. Oncologic and pregnancy outcomes of fertility-sparing treatment with medroxyprogesterone acetate in women with premalignant and malignant endometrial lesions: A case series
Prognosis for Cancer Confined to a Polyp
When endometrial cancer is caught while it is still confined to a polyp and has not invaded deeper into the uterine wall, the prognosis tends to be favorable. One study of early-stage serous or clear cell cancers limited to a polyp reported five-year disease-free survival of about 93% and pelvic control of about 92%. Only 9% of cases confined to the polyp progressed.20PubMed. Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp: outcomes with and without adjuvant therapy These are encouraging numbers given that serous and clear cell cancers are generally considered more aggressive than the more common endometrioid type.
One complication that can affect prognosis even in polyp-confined disease is positive pelvic washings, meaning cancer cells are found floating in the fluid around the uterus during surgery. A study of serous cancers limited to polyps found that about a quarter of patients had positive washings, and those patients were significantly more likely to develop recurrent disease.21International Journal of Gynecological Pathology. Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp This finding underscores why staging surgery matters even when a cancer looks like it is contained.
Interestingly, whether a cancer is caught because of symptoms or discovered incidentally does not seem to change long-term survival. A study comparing over 500 symptomatic women to more than 100 asymptomatic women who had endometrial cancer within a polyp found no meaningful differences in five-year recurrence-free survival, disease-specific survival, or overall survival between the two groups.22PubMed. The diagnosis of endometrial cancer in women with asymptomatic endometrial polyp does not increase survival rates: an israel gynecologic oncology group study The likely explanation is that polyp-confined cancers tend to be caught at an early stage regardless of how they come to attention.
Follow-Up After Polyp Removal
Even when a polyp is entirely benign, recurrence is common enough that follow-up monitoring is standard. After hysteroscopic polypectomy, one follow-up protocol involves transvaginal ultrasound and clinical evaluation at six months, then yearly for women without symptoms. If abnormal bleeding returns or ultrasound shows concerning findings like a thickened lining or a new focal lesion, repeat hysteroscopy is performed.23PubMed Central. Comprehensive Analysis of Risk Factors for Recurrence in Women of Reproductive Age Undergoing Hysteroscopic Polypectomy For women whose polyps contained atypical hyperplasia or cancer and who opted for conservative treatment to preserve fertility, follow-up is considerably more intensive and often includes repeat biopsies at regular intervals.
Conditions That Mimic Cancerous Polyps on Imaging
Not everything that looks like a suspicious polyp on ultrasound or MRI is one. Polypoid adenomyomas, for instance, are benign growths composed of smooth muscle and endometrial glands that can project into the uterine cavity and mimic polyps. On MRI, adenomyomas are more likely than endometrial polyps to contain cystic areas and hemorrhage, and they can occasionally show what looks like invasion into the uterine wall, further mimicking cancer.24PubMed Central. MR imaging findings differentiating uterine submucosal polypoid adenomyomas from endometrial polyps Submucosal fibroids can also protrude into the cavity and look polyp-like on imaging. The ability of modern color Doppler ultrasound to tell these apart is reasonably good but not perfect, which is part of why tissue sampling remains essential when there is any concern.25PubMed Central. Diagnostic value of different color ultrasound diagnostic method in endometrial lesions
Racial Disparities in Diagnosis and Treatment
Access to timely diagnosis and appropriate treatment for uterine cancers is not equal across all groups. In the United States, Black patients with abnormal uterine bleeding are more likely than White patients to experience delays before receiving a diagnosis. One study of Medicaid beneficiaries found that Black patients had roughly 70% higher odds of a delayed diagnosis and nearly twice the odds of not receiving guideline-recommended diagnostic procedures compared to White patients. Even when they did receive the right workup, they were still more likely to face delays in getting to their first diagnostic procedure.26JNCI: Journal of the National Cancer Institute. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries
These delays matter because they compound at each step. Research has shown that Black women with endometrial cancer are less likely to undergo surgery and more likely to receive radiation as a first treatment, even when their cancer is localized. In a large study of over 23,000 women with low-risk early-stage endometrial cancer, Black women were significantly less likely to undergo hysterectomy than White women.27PubMed Central. Racioethnic Disparities in Endometrial Cancer Outcomes The reasons are complex, involving insurance barriers, differing levels of trust in the healthcare system, implicit bias, and structural factors that affect which patients are referred for specialty care. For any woman experiencing unexplained uterine bleeding, understanding that prompt evaluation matters and advocating for timely workup is a practical step that can make a real difference.